JP5149388B2 - 黄斑変性症を処置するための組成物及び方法 - Google Patents

黄斑変性症を処置するための組成物及び方法 Download PDF

Info

Publication number
JP5149388B2
JP5149388B2 JP2010524874A JP2010524874A JP5149388B2 JP 5149388 B2 JP5149388 B2 JP 5149388B2 JP 2010524874 A JP2010524874 A JP 2010524874A JP 2010524874 A JP2010524874 A JP 2010524874A JP 5149388 B2 JP5149388 B2 JP 5149388B2
Authority
JP
Japan
Prior art keywords
composition
retinoid
group
substituted
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010524874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539168A5 (https=
JP2010539168A (ja
Inventor
ワシントン，イリアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40452355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5149388(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of JP2010539168A publication Critical patent/JP2010539168A/ja
Publication of JP2010539168A5 publication Critical patent/JP2010539168A5/ja
Application granted granted Critical
Publication of JP5149388B2 publication Critical patent/JP5149388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2010524874A 2007-09-12 2008-09-12 黄斑変性症を処置するための組成物及び方法 Active JP5149388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99337907P 2007-09-12 2007-09-12
US60/993,379 2007-09-12
PCT/US2008/010676 WO2009035673A1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012260971A Division JP5695017B2 (ja) 2007-09-12 2012-11-29 黄斑変性症を処置するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2010539168A JP2010539168A (ja) 2010-12-16
JP2010539168A5 JP2010539168A5 (https=) 2011-11-04
JP5149388B2 true JP5149388B2 (ja) 2013-02-20

Family

ID=40452355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010524874A Active JP5149388B2 (ja) 2007-09-12 2008-09-12 黄斑変性症を処置するための組成物及び方法
JP2012260971A Active JP5695017B2 (ja) 2007-09-12 2012-11-29 黄斑変性症を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012260971A Active JP5695017B2 (ja) 2007-09-12 2012-11-29 黄斑変性症を処置するための組成物及び方法

Country Status (8)

Country Link
US (4) USRE47045E1 (https=)
EP (2) EP2187880B1 (https=)
JP (2) JP5149388B2 (https=)
DK (1) DK2187880T3 (https=)
ES (1) ES2449150T3 (https=)
PL (1) PL2187880T3 (https=)
PT (1) PT2187880E (https=)
WO (1) WO2009035673A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ587006A (en) 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US20090312438A1 (en) * 2008-06-13 2009-12-17 Bernstein Paul S Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium
CN102612375B (zh) 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
CN107308143A (zh) 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
JP6576636B2 (ja) 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
ES3012058T3 (en) * 2014-02-13 2025-04-08 Katairo Gmbh Compounds for the treatment of lipofuscin related diseases
US20170112792A1 (en) * 2014-03-21 2017-04-27 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
KR102276424B1 (ko) * 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
US9173915B1 (en) 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US20200025685A1 (en) * 2016-12-15 2020-01-23 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
CN118121573B (zh) * 2022-12-01 2025-08-05 复旦大学 一种氘代维生素a及其衍生物的用途
EP4731619A2 (en) * 2023-06-20 2026-04-29 The Trustees Of Columbia University In The City Of New York Novel co-drug, co-administration, and sequential administration of bispecific rbp4/ttr ligand and c20-d3-retinol
AU2024312789A1 (en) * 2023-06-20 2026-01-29 Rensselaer Polytechnic Institute Novel co-drug, co-administration, and sequential administration of selective ttr ligand and c20-d3-retinol
WO2025147228A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate
WO2025147467A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. 10mg to 35mg of gildeuretinol for use in the treatment of stargardt disease
WO2025153898A1 (en) * 2024-01-19 2025-07-24 Gene Company Pty Ltd Retinoid compositions and methods of use
WO2026050657A1 (en) 2024-08-30 2026-03-05 Alkeus Pharmaceuticals, Inc. Gildeuretinol for use for treating geographic atrophy and neovascular age-related macular degeneration
CN120441428A (zh) * 2025-05-15 2025-08-08 复旦大学 一种双异戊二烯衍生物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5508456A (en) * 1993-07-30 1996-04-16 Ligand Pharmaceuticals Incorporated 9-cis tritium-labeled retinoids and intermediates, methods for their synthesis and methods for their use in discovering retinoid X receptor ligands
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6593104B1 (en) 1999-02-12 2003-07-15 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
CA2385475A1 (en) 1999-08-16 2001-02-22 Human Genome Sciences, Inc. 18 human secreted proteins
US20040009907A1 (en) 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
EP1368296A1 (en) 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
US6660297B2 (en) 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
US20040121407A1 (en) 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
JP2006516027A (ja) 2002-12-02 2006-06-15 ジェンベク、インコーポレイティッド 眼関連障害の治療用材料および治療方法
JP2006526662A (ja) 2003-06-05 2006-11-24 アシュカル，チャールズ 過増殖性細胞疾患を治療する方法
US7267830B2 (en) 2003-12-19 2007-09-11 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
FR2864871A1 (fr) 2004-01-06 2005-07-08 Thomson Licensing Sa Methode de decouverte d'un reseau domestique et appareil implementant la methode
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
EP1804788A4 (en) 2004-10-25 2008-05-21 Sirion Therapeutics Inc DETECTION AND ANALYSIS OF FLUORESCENT MOLECULES RELATING TO OPHTHALMOLOGY
JP2008519054A (ja) 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
JPWO2007037188A1 (ja) * 2005-09-27 2009-04-09 北海道公立大学法人 札幌医科大学 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
US8677809B2 (en) 2008-06-16 2014-03-25 Oxford Instruments Plc Thermal measurements using multiple frequency atomic force microscopy
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
ES2469849T3 (es) 2009-06-18 2014-06-20 Concert Pharmaceuticals Inc. Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa

Also Published As

Publication number Publication date
PL2187880T3 (pl) 2014-05-30
WO2009035673A8 (en) 2009-07-02
PT2187880E (pt) 2014-03-25
US20110034554A1 (en) 2011-02-10
US8877809B2 (en) 2014-11-04
US20150133549A1 (en) 2015-05-14
EP2187880A4 (en) 2010-09-08
US9486432B2 (en) 2016-11-08
ES2449150T3 (es) 2014-03-18
USRE47045E1 (en) 2018-09-18
JP5695017B2 (ja) 2015-04-01
JP2013049711A (ja) 2013-03-14
WO2009035673A1 (en) 2009-03-19
JP2010539168A (ja) 2010-12-16
EP2187880A1 (en) 2010-05-26
US20170128403A1 (en) 2017-05-11
EP2687208A1 (en) 2014-01-22
DK2187880T3 (da) 2014-03-10
EP2187880B1 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
JP5149388B2 (ja) 黄斑変性症を処置するための組成物及び方法
CA2266378C (en) Use of sibutramine analogues to lower lipid levels
JP7132630B2 (ja) 同位体修飾成分及びその治療上の使用
US20080114066A1 (en) Synergistic Effects Of Docosahexaenoic Acid (DHA) And Carotenoid Absorption Of Cognitive Function
US9849096B2 (en) Neuroprotective effect of carotenoids in brain
JP2010539168A5 (https=)
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
HUE028065T2 (en) Preparations for the treatment of neurological disorders
ES2251097T3 (es) Tratamiento con cromo/biotina de la diabetes tipo ii.
US20260102392A1 (en) Prophylactic or therapeutic drug for neurodegenerative diseases
EP2651251B1 (en) Composition for the treatment of infertility
US20080200555A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2006091761A1 (en) Methods for treatment of retinal degenerative disease
US20060004096A1 (en) Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
US20060258754A1 (en) Method of treating endothelial dysfunction, oxidative stress and related diseases
CN114615979A (zh) 用于治疗孤独症谱系障碍的伐菲德司他
ITRM960488A1 (it) Integratore dietetico per la prevenzione ed il trattamento della dege nerazione maculare senile
JPS58167511A (ja) 血清脂質代謝改善並びに動脈硬化防止剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110912

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110930

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20111026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121129

R150 Certificate of patent or registration of utility model

Ref document number: 5149388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151207

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250